Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
about
c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlationReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsFunctional deregulation of KIT: link to mast cell proliferative diseases and other neoplasmsSystemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcomePhenotypic and genotypic characteristics of mastocytosis according to the age of onset.Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturationClinical and biologic diversity of leukemias occurring in patients with mastocytosis.Mastocytosis: recent advances in defining the disease.Cutaneous mastocytosis associated with a mixed germ cell tumour of the ovary: report of a case and review of the literature.The expression of melanoma inhibitory activity on mast cells in child patients with cutaneous mastocytosis.A possible mechanism of mast cell proliferation in mastocytosis.Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.Class III receptor tyrosine kinases: role in leukaemogenesis.Recent advances in the understanding of mastocytosis: the role of KIT mutations.Receptor tyrosine kinase mutations in myeloid neoplasms.Mastocytosis in childhood.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Diagnosis and treatment of systemic mastocytosis: state of the art.Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.Mastocytosis: pathology, genetics, and current options for therapy.Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.Clonality and molecular pathogenesis of mastocytosis.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderSystemic mastocytosis with diffuse cutaneous involvement and haematological disease presenting in utero treated unsuccessfully with vincristine.Cutaneous mastocytosis: a review focusing on the pediatric population.KIT and mastocytosis.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.Diagnosis, progression patterns and prognostication in mastocytosis.Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.Anesthetic considerations in pediatric mastocytosis: a review.Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Primary mast cell disorders in children.Paediatric mastocytosis: a systematic review of 1747 cases.Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.Pediatric dermatohistopathology--histopathology of skin diseases in newborns and infants.Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.
P2860
Q24685927-CCC83516-40BD-4FDA-95D8-2FEB74F9382CQ26740953-38990426-3243-486F-B450-27D8F6E8B6CDQ26995624-656DF1A2-27B3-46FB-9B29-E492BED61279Q33168552-66710007-AAA8-45E9-BCBD-C7A784D7FD94Q33327689-AE8FAD01-8C11-40D6-826C-5B2F41AF5973Q33925269-5D8F7654-427C-48F5-88FF-77872D751B82Q34066643-C22EDF79-B463-490C-87EC-BA481ECFA8EEQ34216451-2D1A608C-F39E-4B78-9CA3-2B60AFB42281Q34352682-8402D709-42E5-4170-A30C-ED9D1106CE45Q34403961-1AE0D461-2C01-48B1-A521-18CC76FCAFC5Q34523898-053FF07D-7D86-408F-9DE3-50892375A1BBQ34533831-A32E3186-876F-4E17-86F1-BAEDCB57175AQ34557003-E42DB239-3CA8-4015-8E13-F81FB18D8412Q34635424-34FA677C-7CCF-4812-91B1-4236E7931B96Q34655403-CD6BAC3B-0163-47D9-9A6B-4E69F0A8214CQ34969725-39937ADF-9507-4434-9BE4-2BB9E83B4D81Q35186888-014F5F46-E377-4729-81FB-2E3C6614A15AQ35203889-0EBFEDED-61AD-4931-94D8-3D58B924973BQ35807869-CD3FD424-A4B7-4ED7-925C-2282D8EF07ECQ35835111-33D564F0-FB28-44C6-B570-EA83EA77BA66Q35994902-4F149CE8-27DF-44CD-AC26-4841A07FA5BEQ36182744-515E1506-69DA-49B6-8C6E-E29B02865EB9Q36182758-E2006734-378E-44EA-9302-CF47BB3EDFBBQ36210845-E3A98365-7E3E-4478-87FA-51B633F10B37Q36993464-29181E2E-7060-4E91-9F6F-5DD3F9BEF5C2Q37173105-13B1188A-F515-48FF-9491-1CA0A6C7993EQ37195681-0F755A87-A523-45CF-B1BB-5FC069877B00Q37379320-2FB96617-25BA-41B9-B52D-7B909A27BDB3Q37810130-F9BE84A6-0CD8-438B-9087-55C2FF42EE7FQ37992835-DA7F62A7-8EDB-4D50-896C-944DF6ED91E1Q38025156-6BCA112C-B0BB-40FC-A633-447C5A05877CQ38041575-6EFA6FFC-96A2-43C1-B194-722BBAA65FC6Q38081373-51F7F845-0F2A-4D6A-9A8B-6302CCCC018DQ38110527-656B44C9-6DBE-4F7F-9A83-1FE5D1E6A2F8Q38154827-971B7041-E8D1-473A-9745-EB4BBDA2F1D9Q38348047-473F5105-7494-476B-A9C5-86BF0BBFD3F7Q38358282-AAE082A1-65BE-437C-9CA8-101B65DC3697Q38431102-A148D8EB-C520-4438-8B79-1297A1D6F7E6Q38505061-7D4DE46A-C635-42E1-B231-D28B17DF2880Q39267824-49255705-1651-493C-B584-F00D75B799D7
P2860
Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Identification of activating c ...... r divergent clinical behavior.
@en
type
label
Identification of activating c ...... r divergent clinical behavior.
@en
prefLabel
Identification of activating c ...... r divergent clinical behavior.
@en
P2093
P1476
Identification of activating c ...... r divergent clinical behavior.
@en
P2093
P304
P356
10.1046/J.1523-1747.1998.00414.X
P407
P577
1998-12-01T00:00:00Z
P5875
P6179
1010825915